AbbVie (ABBV) Gains from Investment Securities (2012 - 2026)

AbbVie (ABBV) has 15 years of Gains from Investment Securities data on file, last reported at $266.0 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $266.0 million, up 800.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $307.0 million (down 90.01% YoY), and the FY2025 annual result was $3.0 million, down 99.92% from the prior year.
• Gains from Investment Securities climbed to $266.0 million in Q1 2026 per ABBV's latest filing, from -$4.1 billion in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $4.5 billion in Q4 2023 and troughed at -$4.1 billion in Q4 2025.
• A 5-year average of $600.7 million and a median of $303.0 million in 2024 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities slumped 1087.79% in 2023, then soared 1301.0% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $86.0 million in 2022, then surged by 5083.72% to $4.5 billion in 2023, then tumbled by 42.33% to $2.6 billion in 2024, then plunged by 258.42% to -$4.1 billion in 2025, then jumped by 106.53% to $266.0 million in 2026.
• Business Quant data shows ABBV's Gains from Investment Securities at $266.0 million in Q1 2026, -$4.1 billion in Q4 2025, and $2.8 billion in Q3 2025.